Medscape is available in 5 Language Editions – Choose your Edition here.


Radical Cystectomy

  • Author: Michael Christopher Large, MD; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
Updated: Dec 04, 2014


In the United States, bladder cancer is the fifth most common cancer (following lung, colon, prostate, and breast cancers), fourth in prevalence among men and eighth among women. More than 90% of bladder cancers are transitional cell in origin, while, in countries with high endemic schistosomiasis rates (eg, Egypt), squamous cell carcinoma (SCC) of the bladder is more common.

Lesions limited to the urothelium (pCIS), mucosa (pTa), or lamina propria (pT1) represent 70%-80% of all newly diagnosed bladder cancer cases. Although prone to recurrences and, less commonly, progression to higher-stage disease, these lesions are typically managed with transurethral resection and selectively with intravesical chemotherapy, such as bacille Calmette-Guérin (BCG), mitomycin, or thiotepa. Patients with pT1 disease, particularly those with high-risk features (eg, multifocality, recurrence after intravesical therapy, extensive lamina propria invasion, concomitant carcinoma in situ [CIS]) are at considerable risk of disease progression and may benefit from early radical cystoprostatectomy.

Muscle-invasive bladder cancer, defined as tumors that invade the muscularis propria (pT2 or higher), requires more intensive therapy. To date, surgical resection via radical cystoprostatectomy (bladder and prostate) and pelvic lymph node dissection remain the criterion standard for determining accurate pathologic staging, optimizing curative potential, and minimizing the risk of tumor recurrence.


History of the Procedure

The first record of a radical cystectomy dates to the late 1800s. In 1949, Marshall and Whitmore described the basic surgical principles of radical cystoprostatectomy. In 1987, following the neuroanatomic mapping of the pelvic plexus by Schlegel and Walsh, nerve-sparing cystectomy became a surgical option that allowed for preservation of sexual function.[1]

For many years, radical cystectomy carried a significant perioperative mortality rate (5%-10%). However, presumably because of improvements in surgical technique, the evolution of intensive care medicine, and the availability of new antibiotics, radical cystectomy is now a common procedure in major medical centers and carries a perioperative mortality rate of approximately 1%-2%.[2] At high-volume centers with postoperative pathway care programs, an ICU stay is no longer routine and the median hospital stay is approximately 7 days.



Bladder cancer can be axiomatically subdivided into non–muscle invasive and muscle-invasive disease. This article focuses primarily on the management of muscle-invasive transitional cell carcinoma (TCC) and the role of radical cystectomy. For a more in-depth review of the management of non–muscle invasive bladder cancer, see Bladder Cancer.




United States

  • More than 90% of bladder cancers are TCC.
  • Bladder cancer diagnoses increased by 36% from 1984-1993.
  • In the United States, up to 600,000 people have bladder cancer. In 2008, an estimated 68,000 new cases of bladder cancer were diagnosed, and 14,000 persons died of the disease. [3]
  • In 2008, the male-to-female incidence ratio was 2.9:1, and the male-to-female mortality ratio is 2.4:1. [3]
  • Bladder cancer is more common in whites than in African Americans.
  • The average age at diagnosis is 65 years.
  • Screening of asymptomatic individuals is not currently recommended.


  • In 1996, an estimated 310,000 new cases of bladder cancer were diagnosed worldwide.
  • The incidence rate in Western Europe and North America is higher than in East Asian countries.
  • In developing countries, many bladder cancers are SCCs caused by the parasite Schistosoma haematobium. In high-prevalence regions, SCC of the bladder has enormous health implications (eg, SCC is the most common solid tumor in Egyptian men).


Environmental risk factors

See the list below:

  • Tobacco use accounts for up to 50% of all bladder cancer cases; people who smoke heavily quintuple their risk. Former smokers are at less of a risk for the disease than active smokers. The risk associated with second-hand smoke is unclear.
  • Exposure to aromatic amines found in some dyes, paints, solvents, leather dust, inks, combustion products, rubbers, and textiles is a risk factor.
  • Prior radiation therapy is a risk factor. Women who have undergone pelvic radiation (eg, for cervical cancer) have a 2- to 4-fold increased incidence rate; survival rates are poorer in men who have undergone radiation for prostate cancer than in men of similar age and stage who have not undergone radiation. [4]
  • Treatment with cyclophosphamide (Cytoxan, Neosar) and ifosfamide (Ifex) may lead to the development of bladder cancer through their metabolite acrolein. Following high-dose cyclophosphamide treatment, the 12-year prevalence of bladder cancer is as high as 11%.
  • Low daily fluid intake may be a contributing factor; the relative risk in persons who drink 6 cups of water per day is 0.49 compared with that in persons who drink one cup of water per day.
  • Schistosomiasis caused by the parasite S haematobium can cause SCC; this is common in Egypt and the Nile River Valley.
  • Long-term phenacetin use is a risk factor; this agent is no longer approved for use in the United States.
  • Long-term placement of indwelling catheters is a risk factor; patients who have indwelling catheters for longer than 10 years should undergo bladder surveillance via cytology and cystoscopy.
  • Artificial sweeteners (saccharin, cyclamate), when administered in high doses to laboratory animals, are risk factors for bladder cancer; no similar evidence has been shown in humans.
  • The use of Aristolochia fangchi, a Chinese herb, has been implicated as a risk factor for both upper and lower tract TCC.
  • Coffee and tea are not risk factors for bladder cancer.


As with most neoplasms, bladder carcinogenesis is a complex multistep process that is not fully understood. Activation of proto-oncogenes, loss or inactivation of tumor suppressor genes, and abnormal growth factor or receptor expression have been implicated.

Multiple mutations of chromosome 9 have been identified in superficial bladder cancer cells. Increased expression of the epidermal growth factor receptor and increased mutations of tumor suppressor genes (eg, TP53 and Rb) are common in patients with advanced bladder cancer. Mutations and nuclear accumulation of TP53 have been correlated with an increased grade, stage, and recurrence risk.

The risk of progression to muscle-invasive disease is associated with tumor grade, stage (Ta vs T1), size, number of lesions (solitary vs multiple lesions), previous tumor recurrence, and presence of CIS.



Gross or microscopic hematuria is the initial presenting sign in 80%-90% of patients. Approximately 20% of patients have irritative symptoms such as urinary urgency, dysuria, or frequency. This presentation is typical in patients with diffuse CIS, which can be confused with a urinary tract infection and can result in a delayed diagnosis. With the more routine use of cross-sectional imaging, many bladder lesions are incidentally diagnosed. Patients with muscle-invasive disease can present with incidental or symptomatic obstructive hydroureteronephrosis or, less commonly, with metastatic deposits. These factors make bladder cancer a very uncommon incidental finding on autopsy.



Indications for radical cystectomy include the following:

  • Infiltrating muscle-invasive bladder cancer without evidence of metastasis or with low-volume, resectable locoregional metastases (stage T2-T3b)
  • Superficial bladder tumors characterized by any of the following:
    • Refractory to cystoscopic resection and intravesical chemotherapy or immunotherapy (Up to 71% of these patients may progress to stage T2 within 5 years of initial recurrence.[5] )
    • Extensive disease not amenable to cystoscopic resection
    • Invasive prostatic urethral involvement
  • Stage-pT1, grade-3 tumors unresponsive to intravesical BCG vaccine therapy
  • CIS refractory to intravesical immunotherapy or chemotherapy
  • Palliation for pain, bleeding, or urinary frequency
  • Primary adenocarcinoma, SCC, or sarcoma

Indications for urethrectomy include the following:

  • Tumor in the anterior urethra
  • Prostatic stromal invasion that is noncontiguous with the primary
  • Positive urethral margin during radical cystectomy
  • Diffuse CIS of bladder, prostatic ducts, or prostatic urethra (a relative indication)

Rarely, radical cystoprostatectomy is indicated for salvage treatment for recurrent prostate cancer or intractable hematuria following primary therapy with radiation.


Relevant Anatomy

The bladder is an extraperitoneal muscular urine reservoir that lies behind the pubis symphysis in the pelvis. At the dome of the bladder lies the median umbilical ligament, a fibrous cord that is anchored to the umbilicus and that represents the obliterated urachus. This ligament contains vessels that must be ligated when divided. The ureters, which transport urine from kidney to bladder, approach the bladder obliquely and posterosuperiorly, entering at the trigone. The intravesical ureteral orifices are roughly 2-3 cm apart and form the superolateral borders of the trigone. The trigone consists of the area between the interureteric ridge and the bladder neck. The bladder neck serves as an internal sphincter, which is sacrificed during a radical cystectomy.

In males, the seminal vesicles, vas deferens, ureters, and rectum border the inferoposterior aspect of the bladder. Anterior to the bladder is the space of Retzius, which is composed of fibroadipose tissue and the prevesical fascia. The dome and posterior surface of the bladder are covered by parietal peritoneum, which reflects superiorly to the seminal vesicles and is continuous with the anterior rectal peritoneum. In females, the posterior peritoneal reflection is continuous with the uterus and vagina.

The vascular supply to the bladder arrives primarily via the internal iliac (hypogastric) arteries, branching into the superior, middle, and inferior vesical arteries, which are often recognizable as lateral and posterior pedicles. The arterial supply also arrives via the obturator and inferior gluteal artery and, in females, via the uterine and vaginal arteries. Bladder venous drainage is a rich network that often parallels the named arterial vessels, most of which ultimately drain into the internal iliac vein.

Recent extensive anatomic pathology studies have determined that initial lymphatic drainage from the bladder is primarily into the external iliac, obturator, internal iliac (hypogastric), and common iliac nodes. Following the drainage to these sentinel pelvic regions, spread may continue to the presacral, paracaval, interaortocaval, and paraaortic lymph node chains. For a more detailed explanation of lymphatic drainage, see Treatment.

For more information about the relevant anatomy, see Bladder Anatomy.



Contraindications to radical cystectomy include (1) bleeding diathesis, (2) evidence of gross, unresectable metastatic disease (unless performed for palliation), and (3) medical comorbidities that preclude operative intervention (eg, advanced heart disease, poor pulmonary mechanics, advanced age).

Contributor Information and Disclosures

Michael Christopher Large, MD Fellow, Urologic Oncology, University of Chicago Hospitals

Michael Christopher Large, MD is a member of the following medical societies: American Urological Association, Endourological Society

Disclosure: Nothing to disclose.


Scott E Eggener, MD Assistant Professor of Surgery/Urology, University of Chicago Hospitals

Scott E Eggener, MD is a member of the following medical societies: American Urological Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Bradley Fields Schwartz, DO, FACS Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine

Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, Society of Laparoendoscopic Surgeons, Society of University Urologists, Association of Military Osteopathic Physicians and Surgeons, American Urological Association, Endourological Society

Disclosure: Nothing to disclose.

Additional Contributors

Richard A Santucci, MD, FACS Specialist-in-Chief, Department of Urology, Detroit Medical Center; Chief of Urology, Detroit Receiving Hospital; Director, The Center for Urologic Reconstruction; Clinical Professor of Urology, Michigan State University College of Medicine

Richard A Santucci, MD, FACS is a member of the following medical societies: American College of Surgeons, Societe Internationale d'Urologie (International Society of Urology), American Urological Association

Disclosure: Nothing to disclose.

  1. Schlegel PN, Walsh PC. Neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function. J Urol. 1987 Dec. 138(6):1402-6. [Medline].

  2. Quek ML, Stein JP, Daneshmand S, Miranda G, Thangathurai D, Roffey P. A critical analysis of perioperative mortality from radical cystectomy. J Urol. 2006 Mar. 175(3 Pt 1):886-9; discussion 889-90. [Medline].

  3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr. 58(2):71-96. [Medline].

  4. Bostrom PJ, Soloway MS, Manoharan M, Ayyathurai R, Samavedi S. Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy. J Urol. 2008 Jan. 179(1):91-5; discussion 95. [Medline].

  5. Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol. 2007 Apr. 177(4):1283-6; discussion 1286. [Medline].

  6. Deserno WM, Harisinghani MG, Taupitz M, Jager GJ, Witjes JA, Mulders PF, et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology. 2004 Nov. 233(2):449-56. [Medline].

  7. Gofrit ON, Mishani E, Orevi M, Klein M, Freedman N, Pode D, et al. Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol. 2006 Sep. 176(3):940-4; discussion 944. [Medline].

  8. Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton MA, Bram LL. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology. 1995 Mar. 45(3):387-96; discussion 396-7. [Medline].

  9. Larsson P, Wijkström H, Thorstenson A, Adolfsson J, Norming U, Wiklund P, et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol. 2003. 37(3):195-201. [Medline].

  10. Roberts JT, von der Maase H, Sengeløv L, Conte PF, Dogliotti L, Oliver T. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol. 2006 May. 17 Suppl 5:v118-v122. [Medline].

  11. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005 Jul 20. 23(21):4602-8. [Medline].

  12. Gofrit ON, Nof R, Meirovitz A, Pode D, Frank S, Katz R, et al. Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: A case-control study. Urol Oncol. 2014 Nov 4. [Medline].

  13. Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004 Feb. 171(2 Pt 1):561-9. [Medline].

  14. Sanchez-Ortiz RF, Huang WC, Mick R, et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol. 2003 Jan. 169(1):110-5; discussion 115. [Medline].

  15. Leissner J, Ghoneim MA, Abol-Enein H, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol. 2004 Jan. 171(1):139-44. [Medline].

  16. Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S, Studer UE. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol. 2008 Mar. 179(3):873-8; discussion 878. [Medline].

  17. Zabell JR, Adejoro O, Konety BR, Weight CJ. Risk of End-Stage Kidney Disease after Radical Cystectomy According to Urinary Diversion Type. J Urol. 2014 Oct 31. [Medline].

  18. Herr HW, Bochner BH, Dalbagni G, et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 2002 Mar. 167(3):1295-8. [Medline].

  19. Raj GV, Tal R, Vickers A, Bochner BH, Serio A, Donat SM, et al. Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer. Cancer. 2006 Nov 1. 107(9):2167-72. [Medline].

  20. Pruthi RS, Wallen EM. Robotic assisted laparoscopic radical cystoprostatectomy: operative and pathological outcomes. J Urol. 2007 Sep. 178(3 Pt 1):814-8. [Medline].

  21. Kaul SA, Menon M. Da Vinci assisted cystoprostatectomy and urinary diversion: a paradigm shift in surgical management of bladder cancer. Minerva Urol Nefrol. 2007 Jun. 59(2):149-57. [Medline].

  22. Chang SS, Cole E, Cookson MS, Peterson M, Smith JA Jr. Preservation of the anterior vaginal wall during female radical cystectomy with orthotopic urinary diversion: technique and results. J Urol. 2002 Oct. 168(4 Pt 1):1442-5. [Medline].

  23. Slaton JW, Swanson DA, Grossman HB, et al. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1999 Sep. 162(3 Pt 1):710-4. [Medline].

  24. Boorjian SA, Tollefson MK, Cheville JC, Costello BA, Thapa P, Frank I. Detection of Asymptomatic Recurrence During Routine Oncological Followup After Radical Cystectomy is Associated With Improved Patient Survival. J Urol. 2011 Nov. 186(5):1796-802. [Medline].

  25. Volkmer BG, Kuefer R, Bartsch GC Jr, Gust K, Hautmann RE. Oncological followup after radical cystectomy for bladder cancer-is there any benefit?. J Urol. 2009 Apr. 181(4):1587-93; discussion 1593. [Medline].

  26. Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009 Jan. 55(1):164-74. [Medline].

  27. Mitra AP, Alemozaffar M, Harris BN, Schuckman AK, Skinner EC, Daneshmand S. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy. Urology. 2014 Dec. 84(6):1420-6. [Medline].

  28. Koppie TM, Vickers AJ, Vora K, Dalbagni G, Bochner BH. Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?. Cancer. 2006 Nov 15. 107(10):2368-74. [Medline].

  29. Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol. 2005 Apr 1. 23(10):2358-65. [Medline].

  30. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res. 2006 Dec 15. 12(24):7369-73. [Medline].

  31. Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol. 2005 Sep 20. 23(27):6533-9. [Medline].

  32. Grossman HB, Natale RB, Tangen CM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28. 349(9):859-66. [Medline].

  33. Donat SM, Shabsigh A, Savage C, Cronin AM, Bochner BH, Dalbagni G, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2009 Jan. 55(1):177-85. [Medline].

  34. Nieder AM, Simon MA, Kim SS, Manoharan M, Soloway MS. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Urology. 2006 Apr. 67(4):737-41. [Medline].

  35. Efstathiou JA, Zietman AL, Kaufman DS, Heney NM, Coen JJ, Shipley WU. Bladder-sparing approaches to invasive disease. World J Urol. 2006 Nov. 24(5):517-29. [Medline].

  36. Vallancien G, Abou El Fettouh H, Cathelineau X, et al. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol. 2002 Dec. 168(6):2413-7. [Medline].

  37. Simone G, Papalia R, Leonardo C, Sacco R, Damiano R, Guaglianone S, et al. Prostatic capsule and seminal vesicle-sparing cystectomy: improved functional results, inferior oncologic outcome. Urology. 2008 Jul. 72(1):162-6. [Medline].

  38. Huang J, Xu KW, Yao YS, Guo ZH, Xie WL, Jiang C. Laparoscopic radical cystectomy with orthotopic ileal neobladder: report of 33 cases. Chin Med J (Engl). 2005 Jan 5. 118(1):27-33. [Medline].

  39. Hemal AK, Kolla SB. Comparison of laparoscopic and open radical cystoprostatectomy for localized bladder cancer with 3-year oncological followup: a single surgeon experience. J Urol. 2007 Dec. 178(6):2340-3. [Medline].

  40. Haber GP, Crouzet S, Gill IS. Laparoscopic and robotic assisted radical cystectomy for bladder cancer: a critical analysis. Eur Urol. 2008 Jul. 54(1):54-62. [Medline].

  41. Nuttall M, van der Meulen J, Phillips N, et al. A systematic review and critique of the literature relating hospital or surgeon volume to health outcomes for 3 urological cancer procedures. J Urol. 2004 Dec. 172(6, Part 1 of 2):2145-2152. [Medline].

  42. Barbieri CE, Lee B, Cookson MS, Bingham J, Clark PE, Smith JA Jr, et al. Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol. 2007 Oct. 178(4 Pt 1):1418-21; discussion 1421-2. [Medline].

  43. Gerharz EW, Weingärtner K, Dopatka T, Köhl UN, Basler HD, Riedmiller HN. Quality of life after cystectomy and urinary diversion: results of a retrospective interdisciplinary study. J Urol. 1997 Sep. 158(3 Pt 1):778-85. [Medline].

  44. Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol. 2005 Apr. 173(4):1318-22. [Medline].

  45. Black PC, Brown GA, Dinney CP. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol. 2006 Dec 10. 24(35):5528-35. [Medline].

  46. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol. 2008 Jan. 18(1):1-8. [Medline].

  47. Wang R, Morris DS, Tomlins SA, Lonigro RJ, Tsodikov A, Mehra R, et al. Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. Cancer Res. 2009 May 1. 69(9):3810-8. [Medline].

  48. Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol. 2006 Jul. 176(1):44-7. [Medline].

  49. Undefined. [Medline].

  50. Abol-Enein H, El-Baz M, Abd El-Hameed MA, et al. Lymph node involvement in patients with bladder cancer treated with radical cystectomy: a patho-anatomical study--a single center experience. J Urol. 2004 Nov. 172(5 Pt 1):1818-21. [Medline].

  51. Bales GT, Kim H, Steinberg GD. Surgical therapy for locally advanced bladder cancer. Semin Oncol. 1996 Oct. 23(5):605-13. [Medline].

  52. Bochner BH, Herr HW, Reuter VE. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol. 2001 Dec. 166(6):2295-6. [Medline].

  53. Brössner C, Pycha A, Toth A, Mian C, Kuber W. Does extended lymphadenectomy increase the morbidity of radical cystectomy?. BJU Int. 2004 Jan. 93(1):64-6. [Medline].

  54. deKernion JB, Trapasso JG. Urinary Diversion and Continent Reservoir. Adult and Pediatric Urology. 1996. 2:1465-97.

  55. Dreicer R. Chemotherapy for muscle-invasive bladder cancer in the perioperative setting: current standards. Urol Oncol. 2007 Jan-Feb. 25(1):72-5. [Medline].

  56. El-Gabry EA, Strup SE, Gomella LG. Superficial Bladder Cancer: Current Treatment Modalities and Future Directions: Part II. AUA Update Series. 2000. 20:154-9.

  57. El-Gabry EA, Strup SE, Gomella LG. Superficial Bladder Cancer: Epidemiology, Diagnosis, and Natural History Part I. AUA Update Series. 2000. 19:146-51.

  58. Ghonheim MA. Radical cystectomy. Glenn JF, Graham SD, eds. Glenn's Urologic Surgery. 5th ed. Philadelphia, Pa: Lippincott, Williams & Wilkins; 1998. 187-94.

  59. Gillenwater JY, Grayhack JT, Howards SS. Urothelial Tumors of the Bladder, Upper Tracts, and Prostate. Adult and Pediatric Urology. 1996. 2:1422-31.

  60. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006 Jan 18. 295(3):299-305. [Medline].

  61. Gschwend J, Vieweg J, Fair W. Contemporary Results of Radical Cystectomy for Primary Bladder Cancer. AUA Update Series. 1999. 18:98-103.

  62. Gupta NP, Kolla SB, Seth A, Hemal AK, Dogra PN, Kumar R. Oncological and functional outcome of radical cystectomy in patients with bladder cancer and obstructive uropathy. J Urol. 2007 Oct. 178(4 Pt 1):1206-11; discussion 1211. [Medline].

  63. Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol. 2003 Mar. 169(3):943-5. [Medline].

  64. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001 Jan 1. 19(1):89-93. [Medline].

  65. Herr HW, Bajorin DF, Scher HI, et al. Can p53 help select patients with invasive bladder cancer for bladder preservation?. J Urol. 1999 Jan. 161(1):20-2; discussion 22-3. [Medline].

  66. Herr HW, Donat SM. Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J Urol. 2001 Jan. 165(1):62-4; discussion 64. [Medline].

  67. Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007 Feb. 177(2):437-43. [Medline].

  68. Hollenbeck BK, Montie JE. Early cystectomy for clinical stage T1 bladder cancer. Nat Clin Pract Urol. 2004 Nov. 1(1):4-5. [Medline].

  69. Huang GJ, Stein JP. Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Curr Opin Urol. 2007 Sep. 17(5):369-75. [Medline].

  70. Huguet J, Monllau V, Sabaté S, Rodriguez-Faba O, Algaba F, Palou J. Diagnosis, Risk Factors, and Outcome of Urethral Recurrences Following Radical Cystectomy for Bladder Cancer in 729 Male Patients. Eur Urol. 2007 Jul 5. [Medline].

  71. Inman BA, Harel F, Tiguert R, Lacombe L, Fradet Y. Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patients. J Urol. 2003/11. 170(5):1888-91. [Medline].

  72. International Bladder Cancer Nomogram Consortium, Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006 Aug 20. 24(24):3967-72. [Medline].

  73. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C. Cancer statistics, 2006. CA Cancer J Clin. 2006 Mar-Apr. 56(2):106-30. [Medline].

  74. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol. 2006 Jun. 175(6):2058-62. [Medline].

  75. Kessler TM, Burkhard FC, Perimenis P, Danuser H, Thalmann GN, Hochreiter WW. Attempted nerve sparing surgery and age have a significant effect on urinary continence and erectile function after radical cystoprostatectomy and ileal orthotopic bladder substitution. J Urol. 2004 Oct. 172(4 Pt 1):1323-7. [Medline].

  76. Kessler TM, Burkhard FC, Studer UE. Clinical indications and outcomes with nerve-sparing cystectomy in patients with bladder cancer. Urol Clin North Am. 2005 May. 32(2):165-75. [Medline].

  77. Kim HL, Steinberg GD. The current status of bladder preservation in the treatment of muscle invasive bladder cancer. J Urol. 2000 Sep. 164(3 Pt 1):627-32. [Medline].

  78. McCabe JE, Jibawi A, Javle PM. Radical cystectomy: defining the threshold for a surgeon to achieve optimum outcomes. Postgrad Med J. 2007 Aug. 83(982):556-60. [Medline].

  79. Merseburger AS, Kuczyk MA. The value of bladder-conserving strategies in muscle-invasive bladder carcinoma compared with radical surgery. Curr Opin Urol. 2007 Sep. 17(5):358-62. [Medline].

  80. Montie JE. Against bladder sparing: surgery. J Urol. 1999 Aug. 162(2):452-5; discussion 455-7. [Medline].

  81. Mori K, Nomata K, Noguchi M, Eguchi J, Hayashi N, Kanetake H. Long-term follow up of patients with invasive bladder carcinoma receiving combined cisplatin-based intra-arterial chemotherapy and radiotherapy. Int J Urol. 2007 Jul. 14(7):591-4. [Medline].

  82. Parekh DJ, Bochner BH, Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol. 2006 Dec 10. 24(35):5519-27. [Medline].

  83. Petrovich Z, Baert L, Boyd SD, et al. Management of carcinoma of the bladder. Am J Clin Oncol. 1998 Jun. 21(3):217-22. [Medline].

  84. Pettus JA, Al-Ahmadie H, Barocas DA. Risk of surgical undertreatment with prostate sparing cystectomy: pathologic analysis of 235 radical cystoprostatectomy specimens. Cancer. In Press.

  85. Pettus JA, Al-Ahmadie H, Barocas DA, Koppie TM, Herr H, Donat SM. Risk Assessment of Prostatic Pathology in Patients Undergoing Radical Cystoprostatectomy. Eur Urol. 2007 Jul 26. [Medline].

  86. Schrag D, Hsieh LJ, Rabbani F. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst. 2003 Apr 16. 95(8):588-97. [Medline].

  87. Schumacher MC, Scholz M, Weise ES. Is there an indication for frozen section examination of the ureteral margins during cystectomy for transitional cell carcinoma of the bladder?. J Urol. 2006 Dec. 176(6 Pt 1):2409-13; discussion 2413. [Medline].

  88. Skinner DG, Stein JP, Lieskovsky G, et al. 25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol. 1998. 33 Suppl 4:25-6. [Medline].

  89. Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol. 2003 Jul. 170(1):35-41. [Medline].

  90. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol. 1998 Sep. 160(3 Pt 1):645-59. [Medline].

  91. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001 Feb 1. 19(3):666-75. [Medline].

  92. Sternberg CN. Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation. Semin Oncol. 2007 Apr. 34(2):122-8. [Medline].

  93. Tanagho EA. Anatomy of the genitourinary tract. Tanagho EA, McAninch JW, eds. Smith's General Urology. 14th ed. Norwalk, Conn: Appleton & Lange; 1995. 1-16.

  94. Vieweg J, Gschwend JE, Herr HW, Fair WR. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol. 1999 Feb. 161(2):449-54. [Medline].

  95. Vieweg J, Gschwend JE, Herr HW, Fair WR. The impact of primary stage on survival in patients with lymph node positive bladder cancer. J Urol. 1999 Jan. 161(1):72-6. [Medline].

  96. Weider JA. Intestinal use in the urinary tract. Pocket Guide to Urology. 1999. 23-27.

Mobilizing the lateral peritoneum after transection of the vas deferens with preservation of the spermatic cord.
Pelvic lymph node dissection with removal of lymphatic tissue from the genitofemoral nerve to the obturator nerve and from the pelvic sidewall to above the bifurcation of the iliac vessels.
Mobilization of the distal ureters into the bladder, taking care to preserve vascular supply. The bladder is lifted to the left; the pouch of Douglas is seen between the bladder and rectum.
Exposure and ligation of the lateral pedicle, which extends from the internal iliac vessels over the distal ureter on its way to the bladder.
Opening the pouch of Douglas between the rectum and posterior bladder wall.
Pelvic ileal neobladder ready for anastomosis to the urethra.
The bowel segment of the Indiana pouch includes the entire ascending colon, a small portion of the transverse colon, and about 7-8 cm of the terminal ileum.
The colon has been opened on its antimesenteric border, and the terminal ileum has been plicated by application of the gastrointestinal anastomosis (GIA) stapler to reduce the lumen to approximately 16F. A 14F catheter is shown traversing the efferent limb. The ileocecal valve also has been bolstered with 2-0 absorbable sutures.
Dissection of the lateral pedicle extending from the internal iliac vessels over the distal ureters. These vessels can be ligated, allowing full mobilization of the ureter down to the bladder.
The posterior peritoneum has been entered, and the rectum is retracted to the right. The posterior plane between the bladder and prostate anteriorly and the rectum posteriorly can then be entered using a combination of sharp and blunt dissection; this defines the posterior pedicles.
The rectum is retracted down and to the left, and the articulating stapler is applied to the posterior pedicle. Three such applications of the stapler typically advance the dissection all the way to the lateral endopelvic fascia. The apex can then be addressed in a manner similar to a radical prostatectomy.
The ureters are anastomosed to the posterior wall of the pouch and are shown from behind the pouch. They are brought through the wall and sutured to the pouch with interrupted absorbable 4-0 sutures. An antirefluxing anastomosis has traditionally been recommended, using the LeDuc technique. Both anastomoses are stented.
Table 1. Staging of Bladder Cancer
Disease Type Stage Characteristics
Superficial disease Ta Confined to mucosa
T1 Involving lamina propria and muscularis mucosa
CIS Malignant cells still confined to the flat urothelial layer
Muscle-invasive disease T2 Invasion of muscularis propria
T3 Extension into perivesical fat
T4 Invasion of pelvic sidewall or adjacent organs or metastatic disease
Table 2. Advantages and Disadvantages of Intestinal Segments Used for Urinary Diversion
Segment Advantages Disadvantages
Stomach Can be used in patients with renal failure, hepatic failure, acidosis, and pelvic radiation; no mucus production Hypokalemic hypochloremic metabolic alkalosis, hematuria dysuria syndrome due to acid irritation of the urothelium, concern for increased secondary malignancy
Jejunum N/A Hyperkalemic hypochloremic metabolic acidosis, hyponatremia, osteomalacia (Avoid if at all possible.)
Ileum Familiarity to urologists Hypokalemic hyperchloremic metabolic acidosis, vitamin B-12 deficiency, fat malabsorption, diarrhea, osteomalacia (not a good option following pelvic radiation)
Colon Transverse colon can be used in patients who have had pelvic radiation. Hypokalemic hyperchloremic metabolic acidosis, osteomalacia; most mucus production of all intestinal segments
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.